Six-year follow-up data on survival, benefits for patients with metastatic NSCLC and nivolumab + ipilimumab treatment
Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival ...
Sep 9, 2023
0
1